DXCM vs OGN: which is the better buy in 2026?
DexCom Inc.
NASDAQ:DXCM
Stelo is building a second growth engine in a $60B+ population Dexcom has never monetized, and the stock is trading near trough valuation.
Full DXCM analysisOrganon & Co.
NYSE:OGN
A 3.6x forward P/E spinoff drowning in debt that just happens to throw off half a billion in cash, women's health is the call option.
Full OGN analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is DXCM or OGN the better buy in 2026?
DXCM and OGN are neck and neck at 90/100 on the Compass right now. The better fit depends on which factors matter most to you.
How does Alexandria compare DXCM and OGN?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.